8-K
filed September 11, 2023, 7:59 PM ET
ticker URGN
CIK 0001668243
other material
confidence high
sentiment neutral
materiality 0.30
UroGen Pharma shareholders approve 2017 Plan amendment, elect directors, ratify auditor
UroGen Pharma Ltd.
- Elected eight directors including Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, and Fred E. Cohen.
- Approved amendment to 2017 Equity Incentive Plan increasing authorized shares by 450,000.
- Approved grant of Performance Stock Units to CEO under the amended plan (13,115,279 for, 3,363,390 against).
- Advisory say-on-pay passed with 13,668,197 for, 3,118,618 against, 35,305 abstentions.
- Ratified PricewaterhouseCoopers LLP as independent auditor for next fiscal year (22,507,002 for, 16,731 against).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UroGen Pharma Ltd. shareholders approved Election of Directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal 1 – Election of Directors The shareholders elected the following eight individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UroGen Pharma Ltd. shareholders approved Engagement of PricewaterhouseCoopers LLP as independent auditor.
- Proposal
- auditor ratification
- Outcome
- passed
Exact text from the filing
Proposal 5 - Engagement of PricewaterhouseCoopers LLP as independent auditor. The shareholders approved the engagement of PricewaterhouseCoopers LLP as the Company’s independent auditor until the Company’s 2024 annual meeting of shareholders.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UroGen Pharma Ltd. shareholders approved Performance Stock Units grant to CEO.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 3 – Performance Stock Units The shareholders approved a grant of Performance Stock Units to the Company’s Chief Executive Officer under the 2017 Amended Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UroGen Pharma Ltd. shareholders approved Advisory vote on the compensation of the Company’s named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
Proposal 4 - Advisory vote on the compensation of the Company’s named executive officers. On an advisory basis, the shareholders approved the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
UroGen Pharma Ltd. shareholders approved 2017 Amended Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
Proposal 2 – 2017 Amended Plan. The shareholders approved the 2017 Amended Plan.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.